226 related articles for article (PubMed ID: 20837854)
1. Inhibition of endogenous interferon beta by neutralizing antibodies against recombinant interferon beta.
Sominanda A; Lundkvist M; Fogdell-Hahn A; Hemmer B; Hartung HP; Hillert J; Menge T; Kieseier BC
Arch Neurol; 2010 Sep; 67(9):1095-101. PubMed ID: 20837854
[TBL] [Abstract][Full Text] [Related]
2. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.
Kappos L; Clanet M; Sandberg-Wollheim M; Radue EW; Hartung HP; Hohlfeld R; Xu J; Bennett D; Sandrock A; Goelz S;
Neurology; 2005 Jul; 65(1):40-7. PubMed ID: 16009883
[TBL] [Abstract][Full Text] [Related]
3. Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis.
Deisenhammer F; Schellekens H; Bertolotto A
J Neurol; 2004 Jun; 251 Suppl 2():II31-9. PubMed ID: 15264110
[TBL] [Abstract][Full Text] [Related]
4. Interferon-beta antibodies have a higher affinity in patients with neutralizing antibodies compared to patients with non-neutralizing antibodies.
Gneiss C; Tripp P; Ehling R; Khalil M; Lutterotti A; Egg R; Mayringer I; Künz B; Berger T; Reindl M; Deisenhammer F
J Neuroimmunol; 2006 May; 174(1-2):174-9. PubMed ID: 16556466
[TBL] [Abstract][Full Text] [Related]
5. Neutralizing antibodies to interferon beta-1a and interferon beta-1b in MS patients are cross-reactive.
Khan OA; Dhib-Jalbut SS
Neurology; 1998 Dec; 51(6):1698-702. PubMed ID: 9855525
[TBL] [Abstract][Full Text] [Related]
6. [Significance of neutralizing antibodies to immunomodulatory therapy and their laboratory analysis in multiple sclerosis].
Seres E; Vécsei L
Ideggyogy Sz; 2006 May; 59(5-6):156-62. PubMed ID: 16786710
[TBL] [Abstract][Full Text] [Related]
7. Potential for interferon beta-induced serum antibodies in multiple sclerosis to inhibit endogenous interferon-regulated chemokine/cytokine responses within the central nervous system.
Shapiro AM; Jack CS; Lapierre Y; Arbour N; Bar-Or A; Antel JP
Arch Neurol; 2006 Sep; 63(9):1296-9. PubMed ID: 16966508
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of chemokine expression by interferon beta therapy in patients with multiple sclerosis.
Cepok S; Schreiber H; Hoffmann S; Zhou D; Neuhaus O; von Geldern G; Hochgesand S; Nessler S; Rothhammer V; Lang M; Hartung HP; Hemmer B
Arch Neurol; 2009 Oct; 66(10):1216-23. PubMed ID: 19667211
[TBL] [Abstract][Full Text] [Related]
9. Incidence of antibodies to interferon-beta in patients treated with recombinant human interferon-beta 1a from mammalian cells.
Abdul-Ahad AK; Galazka AR; Revel M; Biffoni M; Borden EC
Cytokines Cell Mol Ther; 1997 Mar; 3(1):27-32. PubMed ID: 9287241
[TBL] [Abstract][Full Text] [Related]
10. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM
Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
[TBL] [Abstract][Full Text] [Related]
11. Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta.
Bertolotto A; Sala A; Caldano M; Capobianco M; Malucchi S; Marnetto F; Gilli F
J Immunol Methods; 2007 Apr; 321(1-2):19-31. PubMed ID: 17335844
[TBL] [Abstract][Full Text] [Related]
12. Determination of interferon beta neutralizing antibodies in multiple sclerosis: improvement of clinical sensitivity of a cytopathic effect assay.
Massart C; Gibassier J; de Seze J; Debouverie M; Moreau T; Pelletier J; Vermersch P; Edan G
Clin Chim Acta; 2008 May; 391(1-2):98-101. PubMed ID: 18249193
[TBL] [Abstract][Full Text] [Related]
13. A novel assay to detect low-titred antibodies to interferon beta in multiple sclerosis patients.
Di Marco P; Pagnotti P; Bellomi F; De Vito G; Sessa E; Bagnato F; Scagnolari C; Bramanti P; Antonelli G
New Microbiol; 2006 Jan; 29(1):11-8. PubMed ID: 16608120
[TBL] [Abstract][Full Text] [Related]
14. The clinical impact of interferon beta antibodies in relapsing-remitting MS.
Perini P; Calabrese M; Biasi G; Gallo P
J Neurol; 2004 Mar; 251(3):305-9. PubMed ID: 15015010
[TBL] [Abstract][Full Text] [Related]
15. Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients.
Lam R; Farrell R; Aziz T; Gibbs E; Giovannoni G; Grossberg S; Oger J
J Immunol Methods; 2008 Jul; 336(2):113-8. PubMed ID: 18511063
[TBL] [Abstract][Full Text] [Related]
16. Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity.
Sominanda A; Rot U; Suoniemi M; Deisenhammer F; Hillert J; Fogdell-Hahn A
Mult Scler; 2007 Mar; 13(2):208-14. PubMed ID: 17439886
[TBL] [Abstract][Full Text] [Related]
17. Neutralizing antibodies to interferon.
Noronha A
Neurology; 2007 Jun; 68(24 Suppl 4):S16-22. PubMed ID: 17562846
[TBL] [Abstract][Full Text] [Related]
18. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy.
Sorensen PS; Koch-Henriksen N; Ross C; Clemmesen KM; Bendtzen K;
Neurology; 2005 Jul; 65(1):33-9. PubMed ID: 15888603
[TBL] [Abstract][Full Text] [Related]
19. Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study.
Pachner AR; Cadavid D; Wolansky L; Skurnick J
Neurology; 2009 Nov; 73(18):1485-92. PubMed ID: 19884576
[TBL] [Abstract][Full Text] [Related]
20. Is the treatment effect of IFN-beta restored after the disappearance of neutralizing antibodies?
Sorensen PS; Koch-Henriksen N; Flachs EM; Bendtzen K
Mult Scler; 2008 Jul; 14(6):837-42. PubMed ID: 18505772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]